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Patients with TARDBP mutations have so far been classified as ALS, sometimes with frontal lobe dysfunction. A 66-
year-old patient progressively developed a severe sensory disorder, followed by a motor disorder, which evolved
over nine years. Symptoms started in the left hand and slowly involved the four limbs. Investigations were
consistent with a mixed sensory and motor neuronopathy. A heterozygous change from an alanine to a proline at
amino acid 382 was identified in exon 6 of the TARDPB gene (p.A382P). This case expands the phenotypic
spectrum associated with mutations in the TARDBP gene and shows that sensory neurons can be severely
damaged early in the course of the disease, following a propagating process, with an orderly progression from a
focal starting point. A combination of severe sensory and motor neuronopathy is rarely encountered in clinical
practice. The possibility of an A382P TDP-43 mutation should be considered in patients with such an association.
Background
TDP-43, a protein involved in RNA processing, is
thought to play a determinant role in the pathophysiol-
ogy of amyotrophic lateral sclerosis (ALS), in which it is
abnormally processed and sequestered in the cytoplasm,
the perikaryon, and dystrophic neurites of neurons [1,2].
Variations in the TARDPB gene, which encodes TDP-
43, occur in about 3% of sporadic and familial cases of
A L S[ 3 ]a n da r em o s t l yf o u n di nc a s e sw i t hau s u a l l y
predominant lower motor neuron involvement and in a
few patients with cognitive deficits [4-6]. We here report
the case of a patient with the A382P TDP-43 mutation
who developed a unique phenotype consisting of a
slowly spreading sensory and motor neuronopathy.
Case presentation
A 72-year-old right-handed non-smoker man was
referred in March 2001 after a 6-year progression of a
sensory, then motor, deficit in the left arm. He reported
that his mother died when she was 56 after a 4-year
evolution of a neurological disease that started in the
upper limbs and progressively paralyzed her, including
speech and deglutition. Symptoms first appeared in the
patient in April 1995, with paresthesia in the left hand
(month 1 = M1). In July (M4), motor deficit and muscle
atrophy were absent, but 128 Hz tuning fork perception
was reduced in the left index finger. Motor conduction
velocities (MCV) and compound motor action potentials
(CMAP) were normal in both the median and ulnar
nerve, while sensory action potentials (SAP) were
reduced in the left median and ulnar nerves and slightly
reduced in the right sural nerve (see Additional file 1
for the electrophysiological methods and the detailed
results of the ENMG study). Needle examination
showed only an increased number of polyphasic motor
unit potentials (MUPs) in the left abductor pollicis bre-
vis (28% of MUPs). The cervical spine and plexus MRI
was normal. Because of persistent paresthesia, somato-
sensory evoked potentials (SEPs) were recorded in
October 1996 (M18) and were normal in the right med-
ian nerve, whereas the left N9 potential amplitude was
reduced and the N13, P14, and N30 potentials abolished
(Table 1).
Four years later, in January 1998 (M35), motor deficit
and muscle atrophy appeared in the left arm, while the
sensory symptoms extended to the elbow. In July (M40),
SAPs were reduced in both the median and ulnar nerve,
predominantly on the left. MCVs and CMAPs were nor-
mal. Needle examination showed chronic neurogenic
changes in the abductor policis brevis, abductor digiti
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radialis longus in both hands, but predominantly on the
left side.
In November 2000 (M68), the left arm showed diffuse
muscular atrophy. Tendon reflexes were abolished and
fasciculations were observed in the left biceps brachii
and pectoralis major. In March 2001 (M72), the motor
deficit was restricted to the left arm, with an MRC score
of 3 in the deltoideus, biceps brachii, triceps brachii, and
abductor pollicis brevis muscles. Muscle atrophy was
restricted to the left upper limb and fasciculations were
observed in all four limbs. Tendon reflexes were absent
in the left arm and normal in the other limbs. The plan-
tar response was indifferent on both sides. Bulbar invol-
vement was absent. Tuning fork 128 Hz perception was
absent at the left wrist and elbow, present at the clavicle,
and reduced at the left ankle and knee. Stereognosia and
graphesthesia were abolished in the left hand, while pain
and thermal sensation were almost normal. There was
no cognitive impairment and no dysautonomic manifes-
tation. SAPs were absent in the left radial, ulnar, and
median nerves and reduced in the other limbs. CMAPs
were reduced in the left median and ulnar nerves and
normal on the right side and in both peroneal and tibial
nerves. Motor conduction velocities and F-wave laten-
cies were normal. Fibrillation potentials were recorded
in the upper limbs and fasciculations were present in
the left vastus lateralis. SEPs were not recordable in the
left median and both tibial nerves, but were normal in
the right median nerve with the exception of a reduced
N9 potential (Table 1).
The motor deficit slowly progressed in the left arm
and, in January 2004 (M104), proximal weakness
appeared in the left leg. The Norris limb score was 45/
63 and the bulbar score 42/42. Forced vital capacity
was normal. SAPs could not be recorded in the upper
limbs and were severely reduced in the lower limbs,
especially on the left side. CMAPs were reduced or
absent in the left median, ulnar, tibial, and peroneal
nerves and reduced in the right median and peroneal
nerves. Conduction velocities were normal. Positive
sharp waves and fibrillation potentials were recorded
in all four limbs. SEPs were abolished in the four
limbs, except in the right median nerve, where a N20
potential was recorded (Table 1). CO2 laser-evoked
potentials (LEPs), evaluating Aδ and C fibers, were
abolished in both hands and feet. The patient died
suddenly in June 2004 (M110). No autopsy was per-
formed. The clinical and neurophysiological data are
summarized in Figure 1.
The following investigations were performed in Octo-
ber 2001 (M79) and were normal: cerebrospinal fluid
analysis, blood cell count, ionogram, serum creatinine,
glycemia, liver enzymes, vitamin E, B12 and folates, TSH,
hexosaminidase A and B, amino acid chromatography,
a n dA p oAa n dA p oB .S e r o l o g yw a sn e g a t i v ef o rH I V ,
VDRL-TPHA, and hepatitis B and C. Screening for
monoclonal gammopathy, red blood cell acanthocytosis,
and antinuclear, anti-SSA, anti-SSB, anti-mitochondrial,
anti-gliadin, anti-disialosyl ganglioside, and anti-
onconeural antibodies, including Hu and CRMP5/CV2
antibodies, was negative. The salivary gland biopsy was
normal. No mutations of the frataxin and TTR genes
were found. X-ray and CT thoracic scans were normal, as
was abdominal ultrasound. A muscle biopsy (left vastus
lateralis) showed neurogenic changes without mitochon-
drial abnormalities.
In December 2001 (M81), a left superficial radial nerve
biopsy was normal on paraffin-embedded H-S and
Congo red-stained sections. Semithin sections disclosed
a severe reduction in large myelinated fiber density
(Figure 2A and 2B). Only a few fibers were degenerating.
Regenerating clusters were absent. Immunohistochemis-
try was performed on formalin-fixed paraffin-embedded
samples of the nerve biopsy from the patient and, as con-
trol, a patient with a sensory neuropathy using rabbit
polyclonal anti-human TDP43 antibodies (Protein Tech
Group, Inc; Chicago, IL, USA) at a 1/1000 dilution.
Nerve sections were deparaffinised, subjected to immu-
nochemical detection with the antibodies, processed with
a ultraView Universal DAB Detection Kit (Ventana Med-
ical Systems, S.A., Illkirch, France), and counterstained
with H-E. In both the patient and control, Schwann cell
Table 1 Evolution of sensory evoked potentials (SEPs)
and sensory action potentials (SAPs) with disease course
RIGHT LEFT
Months 4-18 40 68-72 104 4-18 40 68-72 104
Median nerve
SEPs
N9 + + - + - -
N13 + - ND - - - ND -
P14 + + - - - -
N20 + + + - - -
SAP (μV) N > 8 μV 13.8 12.7 4.75 0 6.8 5 0 0
Tibial nerve
SEPs
N20 ND ND - - ND ND - -
P 3 0 -- --
Sural nerve
SAP (μV) N > 8 μV 7.8 ND 6.4 6.1 8 ND 6.4 3.8
SEPs were recorded after stimulation of the median nerve at the wrist or the
tibial nerve at the ankle, and SAPs were recorded in the median or sural
nerves. N9, Erb point; N13, cervical spinal cord posterior horn; P14, gracilis
and cuneatus nuclei; N20, parietal cortex, and P30, frontal cortex. ‘+’ indicates
a recorded potential and ‘-’an absent potential. ND: not done. SAPs were
dromically registered with surface electrode in the ulnar nerve (head level,
normal ≥ 8 μV) and antidromically in the sural nerve (foot level, normal
≥ 8 μV).
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Page 2 of 7Figure 1 Parallel evolution of electroneuromyographic abnormalities (top row) and clinical sensory and motor perturbations (bottom
row). The slight neurogenic changes were motor unit potentials (MUPs) with increased polyphasism, size, and duration according to multi-MUP
computer-assisted analysis, the active neurogenic changes were fasciculation potentials, fibrillations potentials, or positive sharp waves, while the
chronic neurogenic changes were loss of MUPs or high firing rate. 1, abductor policis brevis; 2, first dorsal interosseus; 3, abductor digiti minimi;
4, extensor carpi radialis longus; 5, brachioradialis; 6, palmaris longus; 7, trapezius; 8, vastus lateralis; 9, gastrocnemius; 10, tibialis anterior; 11,
extensor digitorum brevis; 12, biceps brachialis; 13, deltoidus; 14, mentalis. The bars correspond to sensory action potentials in μV registered
dromically with a surface electrode in the ulnar nerve (head level, normal ≥ 8 μV) and antidromically with the electrode in the sural nerve (foot
level, normal ≥ 8 μV).
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observed in the cytoplasm or in axons (Figure 3). In June
2003, the brain MRI was normal, while the T2 weighted
cervical spine MRI showed a hypersignal in the left pos-
terior column (Figure 2C).
Genetic analysis
The sample was sequenced for mutations in the SOD1,
TARDBP,a n dFUS genes. A previously reported hetero-
zygous change from an alanine to a proline at amino
acid 382 [7], resulting from the substitution of a guanine
by a cytosine at position one of the codon (c.1278G > C),
was identified in exon 6 of the TARDPB gene (p.A382P)
(Figure 4). This variant was not identified in 360 control
participants [8]. Family members were not available for
genetic analysis. The mutated alanine is conserved in
seven out of nine tested species, but is a proline in the
mouse and rat (Figure 4B). Two bioinformatics programs,
Polyphen [9] and SIFT [10], were used to predict the
effect of the polymorphism on the protein. Polyphen pre-
dicted the change to be benign, while SIFT predicted that
it would affect protein function, with a low confidence in
the prediction.
Discussion
This is the first time, to our knowledge, that a variant in
TARDBP has been identified in a patient with a sensory
and motor phenotype. It is very unlikely that this
resulted from a coincidental association of sensory neu-
ropathy and motor neuron disease, since the motor and
sensory manifestations started in the same metameric
territory and followed a parallel course. Moreover, an
extensive work-up found no other cause of sensory neu-
ropathy. Despite the absence of pathological evidence,
the severe sensory involvement is very suggestive of
Figure 2 Fiber loss mainly involved large fibers with a few degenerating axons (arrows) and no regenerating cluster as seen in the
photograph of the superficial radial nerve biopsy (semithin section × 40) in (A) and the histogram in (B), (C), Abnormal hyperintensity
in the left posterior column on the cervical spinal cord T2-MRI.
Figure 3 Immunohistochemical study using anti-TDP-43
antibodies of the patient’s nerve biopsy (A × 40) and a control
nerve biopsy (B × 30). In both nerves, only Schwann cell nuclei
are immunolabeled.
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tion in dorsal root ganglia [11]. Thus, the sensory per-
turbations had a typical non-length-dependent pattern
both clinically and on sensory nerve conduction study.
The presence of SEPs with early absent N13 potentials
and still recordable N9 potentials also suggests sensory
neuronopathy [12]. Moreover, this indicates that the
central process of the sensory neurons was involved
before the peripheral process. Central process degenera-
tion was also demonstrated by the presence of abnormal
signals in the posterior column on spinal cord MRI, as
reported previously [13]. Finally, the CO2 laser-evoked
potentials indicated that, despite a predominant large
neuron involvement, small nociceptive neurons were
also involved.
The patient’s mother’s history was highly suggestive of
neuromuscular disease, arguing for a hereditary trans-
mission of the disorder. The A382P mutation identified
in the patient has been reported in another ALS case,
but the sensory phenotype of this patient was not speci-
fied in the publication [7]. The mutation, which was
absent in 720 control chromosomes [8], was predicted
to have mixed effects by two different bioinformatics
software programs. The missense mutation, which is
also a proline in the rat and mouse, was located in the
C-terminal glycine-rich region, where most TARDPB
mutations have been found [14]. Thus, with the avail-
able information, it can be hypothesized that the
TARDPB variant actually caused the particular pheno-
type of this patient.
Sensory neuron involvement had not previously been
reported for TDP-43 mutations and, when mentioned,
SAPs have been reported as normal [15,16]. Pathological
studies in the few available cases [4,17] and in trans-
genic models [18,19] did not specifically examine dorsal
root ganglia, although TDP-43 is normally expressed in
Figure 4 Sequence traces and across-species conservation. (A) Sequence trace for the p.A382P variant; the patient is shown below the wild
type sequence. The red square marks the substituted nucleotide and the substituted amino acid is in red. (B) Conservation across nine species
of amino acids 377 to 405 of TDP-43 is shown using the Clustal W method. Amino acid 382 is boxed in red and the proline present in the
mouse and rat is underlined in red.
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biopsy, no abnormal accumulation of TDP-43 was found
in peripheral axons, in keeping with the fact that, in the
central nervous system of patients with TARDBP muta-
tions or sporadic ALS, the protein does not accumulate
in axons, but in the neuron cell body and dendrites [1,4].
ALS is usually considered as a propagating process
that recruits locally and spreads with an orderly progres-
sion [21]. In this patient, the electrophysiological results
suggested a pre-existing widespread sensory dysfunction
upon which the degenerative process developed focally
in the left arm, then extended to the contralateral side
and, through descending pathways, to the lumbar
region. At each level, sensory neurons were electrophy-
siologically involved before motor neurons.
The combination of severe sensory and motor neuro-
nopathy is rarely encountered in clinical practice. It has
been reported in patients with paraneoplastic Hu-anti-
bodies, [22] in facial onset sensory and motor neurono-
pathy (FOSMN) [23], and in rare genetic diseases, such
as Tangier disease [24]. The A382P TDP-43 mutation
should be considered in patients with such an
association.
Conclusions
This case broadens the spectrum of neurological syn-
dromes associated with TARDBP mutations. It shows
that, in rare circumstances, sensory neurons can be
involved early and as severely as motor neurons and
provides arguments in favor of the hypothesis that the
disease followed a propagating process, with a spreading
and orderly progression from a focal starting point.
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